Search Result

Results for "

bowel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	15-PGDH (2) 5-HT Receptor (27) ABA Receptor (2) Adenosine Receptor (2) Adrenergic Receptor (4) Akt (14) Aminopeptidase (3) AMPK (8) Amylases (1) Amyloid-β (5) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (9) AP-1 (1) Apical Sodium-Dependent Bile Acid Transporter (3) Apoptosis (39) Arrestin (1) Aryl Hydrocarbon Receptor (3) ATP Synthase (1) ATTECs (1) Aurora Kinase (4) Autophagy (2) Bacterial (23) Bcl-2 Family (2) Beta-secretase (2) Biochemical Assay Reagents (6) Calcium Channel (11) Carboxypeptidase (1) Caspase (10) Cathepsin (1) CCR (8) CD1 (1) CD28 (1) CD3 (1) CDK (2) Cholinesterase (ChE) (1) COX (4) CRFR (2) CX3CR1 (2) CXCR (7) Cytochrome P450 (4) Dihydroorotate Dehydrogenase (3) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (2) Dopamine Transporter (2) Drug Derivative (6) Drug Intermediate (7) Drug Isomer (2) Drug Metabolite (2) Dynamin (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (15) Enteropeptidase (2) Environmental Pollutants (2) Epigenetic Reader Domain (4) Epoxide Hydrolase (1) ERK (11) Estrogen Receptor/ERR (1) FAAH (1) Ferroptosis (5) FLAP (1) Fluorescent Dye (3) Formyl Peptide Receptor (FPR) (1) Fungal (1) FXR (4) Gap Junction Protein (1) GCGR (3) GLP Receptor (5) Glucocorticoid Receptor (3) Glutathione S-transferase (1) GPR109A (1) GPR35 (1) GPR65 (1) GPR68 (1) Guanylate Cyclase (5) HDAC (3) Heme Oxygenase (HO) (5) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (4) Histamine Receptor (1) HIV (4) HSP (1) HyT (1) IAP (1) IFNAR (8) IKK (5) Indoleamine 2,3-Dioxygenase (IDO) (4) Integrin (11) Interleukin Related (67) IRAK (9) Isotope-Labeled Compounds (13) JAK (19) JNK (12) Keap1-Nrf2 (8) Leukotriene Receptor (5) Ligands for Target Protein for PROTAC (1) Lipoxygenase (4) LPL Receptor (1) mAChR (19) METTL3 (2) MHC (1) Mixed Lineage Kinase (5) MMP (1) Motilin Receptor (1) mTOR (2) MyD88 (1) Na+/K+ ATPase (2) nAChR (1) NADPH Oxidase (1) Necroptosis (5) Neurokinin Receptor (5) NF-κB (37) NO Synthase (13) NOD-like Receptor (NLR) (25) Opioid Receptor (13) Orphan Nuclear Receptor (2) P-glycoprotein (1) P2X Receptor (3) P2Y Receptor (4) p38 MAPK (8) Parasite (5) Phosphatase (1) Phosphodiesterase (PDE) (6) Phosphoglycerate Kinase (PGK) (1) PI3K (5) PIKfyve (2) Potassium Channel (10) PPAR (1) Pregnane X Receptor (PXR) (1) Prostaglandin Receptor (4) PROTACs (3) Proteolytic Enzyme (1) Proton Pump (2) Pyroptosis (8) Pyruvate Carboxylase (PC) (1) Reactive Oxygen Species (ROS) (5) Reference Standards (38) RET (3) RIP kinase (8) ROR (3) Salt-inducible Kinase (SIK) (2) Sirtuin (6) SOD (1) Sodium Channel (2) Src (1) STAT (15) STING (2) Succinate Dehydrogenase (3) TGF-beta/Smad (1) TNF Receptor (34) Toll-like Receptor (TLR) (9) TRP Channel (1) Tyrosinase (1) Tyrosine Hydroxylase (1) Virus Protease (4) Wnt (1) Xanthine Oxidase (1) β-catenin (1) β-glucuronidase (1)
By Research Areas:	Cancer (59) Cardiovascular Disease (18) Endocrinology (18) Infection (33) Inflammation/Immunology (289) Metabolic Disease (91) Neurological Disease (77)
Oligonucleotides:	Solvents (1) Liposomal Film-forming Agents (1) Emulsifiers (1) Solubilizing Agents (1) Phospholipids (1) Antisense Oligonucleotides (2)

378

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT IFNAR	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-177080

Emvistegrast GS-1427	Integrin	Inflammation/Immunology
Emvistegrast (GS-1427) is a quinolone derivative. Emvistegrast is also an inhibitor of α4β7 integrin. Emvistegrast can be used to investigate diseases mediated by α4β7 integrin, such as inflammatory bowel disease .

HY-148531

PF-07054894	CCR	Inflammation/Immunology
PF-07054894 is an orally active and potent C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) antagonist that blocks CCR6-mediated chemotaxis with an IC₅₀ value of 5.7 nM in vitro. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease .

HY-173236

STAT4-IN-1	STAT	Metabolic Disease Inflammation/Immunology Cancer
STAT4-IN-1 is an inhibitor of STAT4 with a K_i of 0.35 μM. STAT4-IN-1 is expected to be used in the research of autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes .

HY-111613

Pinaverium bromide 4 Publications Verification	Calcium Channel	Cancer
Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .

HY-B0499A

Otilonium bromide 3 Publications Verification Octylonium bromide; SP63	mAChR	Neurological Disease
Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-174990

HW201877	15-PGDH	Metabolic Disease Inflammation/Immunology
HW201877 is a potent and orally active 15-prostaglandin dehydrogenase (15-PGDH) inhibitor with an IC₅₀ of 3.6 nM. HW201877 demonstrates robust cellular efficacy in elevating PGE2 levels in A549 cells and exhibits remarkable efficacy in animal models of tissue injury and fibrosis. HW201877 can be used for the study of inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease (CD) .

HY-123630

Allura Red AC FD&C RED NO. 40; CI 16035	Environmental Pollutants Fluorescent Dye 5-HT Receptor Interleukin Related Reactive Oxygen Species (ROS) IFNAR	Inflammation/Immunology
Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-14908

Vidofludimus 4 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-12820

Sibofimloc 4 Publications Verification Antibiotic-202	Bacterial Antibiotic	Infection
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .

HY-175222

GlcNAc-MurNAc	Toll-like Receptor (TLR) NF-κB Caspase TNF Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology
GlcNAc-MurNAc, a disaccharide, is a TLR4 agonist with a K_d of 383 μM for murine TLR4. GlcNAc-MurNAc directly binds to TLR4 and activates its downstream NF-κB and IRF pathways. GlcNAc-MurNAc improves Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis in mice through a TLR4-dependent mechanism. GlcNAc-MurNAc can be used for the study of inflammatory bowel disease .

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-102013

Omilancor BT-11	ABA Receptor	Neurological Disease Inflammation/Immunology
Omilancor (BT-11) is an orally active lanthionine synthetase cyclase-like receptor 2 (LANCL2) activator. Omilancor can be used for the study of psoriasis, inflammatory bowel disease (IBD), and Crohn's disease (CD) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-100459

GSK3179106 5 Publications Verification	RET	Metabolic Disease Inflammation/Immunology
GSK3179106 is an orally active and selective RET kinase inhibitor with IC₅₀s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity .

HY-P2221

Glepaglutide 1 Publications Verification ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-44809

Izilendustat	HIF/HIF Prolyl-Hydroxylase Bacterial	Cardiovascular Disease Infection Inflammation/Immunology
Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia .

HY-111191

ONO-2952 1 Publications Verification	Adrenergic Receptor	Neurological Disease
ONO-2952 is a potent, selective and orally active translocator protein 18 kDa (TSPO) antagonist with K_i of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment .

HY-P2221B

Glepaglutide acetate 1 Publications Verification ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-107384A

Asimadoline hydrochloride EMD-61753 hydrochloride	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-162734

BRD5075	GPR65	Inflammation/Immunology
BRD5075 is a selective GPR65 activator. BRD5075 enhances GPR65 activity under acidic conditions, promotes Gαs-dependent signaling pathways, including cAMP production and G protein recruitment. BRD5075 regulates the cytokine and chemokine expression network in dendritic cells, and inhibits the expression of pro-inflammatory cytokines and chemokines in a GPR65-dependent manner. BRD5075 is applicable to research related to inflammatory bowel disease .

HY-124686

ER-464195-01	STAT Interleukin Related TNF Receptor	Inflammation/Immunology
ER-464195-01 is an orally active calreticulin (CRT) and integrin α subunits (ITGAs) binding inhibitor. ER-464195-01 inhibits leukocyte infiltration and subsequent inflammatory cascade reactions by dissociating the binding between CRT and ITGA. ER-464195-01 down-regulates the expression of pro-inflammatory genes (such as TNF-α, IL-1β, IL-6, IL-17f) induced by DSS (HY-116282C), and inhibit the phosphorylation of STAT3 and the production of serum amyloid A (SAA). ER-464195-01 can be used for the study of inflammatory bowel disease (IBD) .

HY-107649

Zamifenacin fumarate UK-76654 fumarate	mAChR	Metabolic Disease
Zamifenacin fumarate (UK-76654 fumarate) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-178761

PGK1-IN-1	Phosphoglycerate Kinase (PGK) Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related	Inflammation/Immunology
PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor (IC₅₀: 33 nM). PGK1-IN-1 inhibits PGK1-mediated glycolytic metabolism and reduces glucose consumption/lactate production. PGK1-IN-1 enhances Nrf2 accumulation and HO-1 expression, and suppresses the transcription and protein levels of the inflammatory cytokines IL-1β and IL-6. PGK1-IN-1 ameliorates Dextran sulfate sodium (DSS) (HY-116282C)-induced experimental colitis in mice. PGK1-IN-1 can be used for research of inflammatory bowel disease (IBD) .

HY-158404

METTL3-IN-8	METTL3	Inflammation/Immunology
METTL3-IN-8 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .

HY-161735

CXCR4-IN-3	CXCR	Inflammation/Immunology
CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor CXCR4, with an IC₅₀ of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-123337

Zamifenacin UK-76654	mAChR	Metabolic Disease
Zamifenacin (UK-76654) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-137789

Tazofelone LY 213829	COX	Cancer
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .

HY-147527

CDK8-IN-5	CDK	Inflammation/Immunology
CDK8-IN-5 is a potent CDK8 inhibitor with an IC₅₀ of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease .

HY-173450

ZL0516	Epigenetic Reader Domain	Inflammation/Immunology
ZL0516 is a potent, selective, and orally active BRD4 BD1 inhibitor. ZL0516 suppresses inflammatory bowel disease (IBD) by inhibiting BRD4/NF-κB signaling .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-15707

NS6180 1 Publications Verification	Potassium Channel	Inflammation/Immunology
NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC₅₀value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .

HY-175310S

Voderdeucitinib	JAK	Inflammation/Immunology
Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .

HY-18263A

Elubrixin SB-656933	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-107384

Asimadoline EMD-61753	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-176265

DDS5	CD28	Inflammation/Immunology
DDS5 is a CD28 inhibitor with a k_d of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC₅₀: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis .

HY-175814

NLRP3-IN-83	NOD-like Receptor (NLR) Pyroptosis Interleukin Related	Inflammation/Immunology
NLRP3-IN-83 is a selective and orally active NLRP3 inflammasome activation inhibitor. NLRP3-IN-83 exhibits good inhibitory IL-1β activity with an IC₅₀ of 1.4 μM by blocking NLRP3, independent of NF-κB signaling. NLRP3-IN-83 only slightly inhibits AIM2 inflammasome pathway, but has no effect on NLRC4 inflammasome. NLRP3-IN-83 prevent cell pyroptosis and exhibits significant anti-inflammatory efficacy in ulcerative colitis model. NLRP3-IN-83 can be used for the study of inflammatory bowel disease (IBD) .

HY-107015A

Prednisolone metazoate sodium Predfoam; ATL 2502	Glucocorticoid Receptor	Inflammation/Immunology
Prednisolone metazoate sodium (ATL 2502) can be used for study of inflammatory bowel disease, ulcerative colitis, and GI disorders .

HY-158403

METTL3-IN-7	METTL3	Inflammation/Immunology
METTL3-IN-7 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .

HY-108171A

Hexocyclium methylsulfate	mAChR	Inflammation/Immunology
Hexocyclium methylsulfate is a potent mAChR antagonist with pK_i values of 8.9, 7.7, 8.4, 8.8 for M1, M2, M3, and M4 subtype, respectively. Hexocyclium methylsulfate has the potential for the research of duodenal ulcer and irritable bowel syndrome .

HY-176771

Tapinarof prodrug-1	Drug Intermediate	Inflammation/Immunology
Tapinarof prodrug-1 (Compound 31) is an orally active prodrug of Tapinarof (HY-109044). Tapinarof is an AhR agonist. Tapinarof prodrug-1 has an improving effect in the TNBS-induced mouse model of inflammatory bowel disease. Tapinarof prodrug-1 can be used in the research of inflammatory diseases .

Cat. No.	Product Name

HY-L078

Gut Microbial Metabolite Library

475 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L103

Anti-Colorectal Cancer Compound Library

2,491 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,491 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L014

NF-κB Signaling Compound Library

1,670 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 1,670 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Type

HY-123630

Allura Red AC

FD&C RED NO. 40; CI 16035

Fluorescent Dye

Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .

HY-114354

BODIPY FL alkyne

BOD FL alkyne

Fluorescent Dye

BODIPY (BOD) FL alkyne is an alkyne-containing BODIPY fluorophore derivative. BODIPY FL alkyne is a bioorthogonal labeling reagent with low toxicity and extremely low non-specific reactivity, and it is widely used in fluorescent bioimaging. BODIPY FL alkyne specifically labels azide groups on intracellular glycoconjugates mainly via strain-promoted azide-alkyne cycloaddition (SPAAC), or mediates site-specific conjugation with proteins such as IL-33, and supports positive cross-linking with other probes (e.g., DBCO-SCy5) for dual labeling. With the advantages of high specificity and low background interference, BODIPY FL alkyne can be used in the research of related diseases such as asthma, atopic dermatitis and inflammatory bowel disease .

HY-123630R

Allura Red AC (Standard)

FD&C RED NO. 40 (Standard); CI 16035 (Standard)

Fluorescent Dye

Allura Red AC (Standard) is an analytical standard of Allura Red AC. This product is intended for research and analytical applications. Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .

Cat. No.	Product Name	Type

HY-108749

Olive oil

Maximum Cited Publications

6 Publications Verification

Cropure OL

Biochemical Assay Reagents

Olive oil (Cropure OL) is an oleaginous compound found in the fruit of the Olea europaea tree . Olive oil contains many phenolic components and exerts antioxidant activity. Olive oil exhibits hydroxyl radical scavenging, platelet aggregation inhibition and xanthine oxidase inhibitory activity. Olive oil can promote wound healing and relieve inflammation. Olive oil can be used for the research of inflammation, cancer, metabolic and cardiovascular disease, such as diabetic foot ulcers and inflammatory bowel disease .

HY-W013636C

2-Ketoglutaric acid potassium

5+ Cited Publications

Alpha-Ketoglutaric acid potassium

Biochemical Assay Reagents

2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC₅₀ value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length .

HY-B0926B

Diatrizoate meglumine N-Methyl-D-glucamine diatrizoate	Biochemical Assay Reagents
Diatrizoate meglumine (N-Methyl-D-glucamine diatrizoate) is an orally active, water-soluble, poorly absorbable iodinated contrast agent. Diatrizoate meglumine is widely used as an adjuvant for radiological diagnosis and can also be applied to studies of small bowel obstruction in non-malignant conditions .

HY-40421

(R)-3-Fluoropyrrolidine hydrochloride	Biochemical Assay Reagents
(R)-3-Fluoropyrrolidine hydrochloride is an intermediate. (R)-3-Fluoropyrrolidine hydrochloride can be used in the synthesis of hVanin-1 inhibitor (Compound X20). (R)-3-Fluoropyrrolidine hydrochloride can be used in the research of inflammatory bowel disease .

HY-W010174

2-Chloro-4-nitropyridine	Biochemical Assay Reagents
2-Chloro-4-nitropyridine is a drug intermediate in synthesizing other organic compounds, such as 2-chloro-4-ethoxypyridine and various RET kinase inhibitors .

Cat. No.	Product Name	Target	Research Area

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT IFNAR	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-17584

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1714

Apraglutide FE 203799	GLP Receptor	Metabolic Disease
Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-P10368

P110 heptapeptide	Dynamin Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-P2221

Glepaglutide 1 Publications Verification ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-129724A

α-MSH (11-13) acetate ACTH-(11-13) acetate; Lys-Pro-Val acetate; H-Lys-Pro-Val-OH acetate		Infection Metabolic Disease
α-MSH (11-13) acetate is a melanocortin-1 receptor ligand and anti-inflammatory agent. α-MSH (11-13) acetate triggers acute intracellular calcium elevation under specific costimulation or pathway inhibition conditions. α-MSH (11-13) acetate inhibits TNF-α-induced NF-κB activation, GPx activity, HIV replication, as well as colony formation of S. aureus and C. albicans. α-MSH (11-13) acetate is applicable to the research of Staphylococcus aureus infection, Candida albicans infection, human immunodeficiency virus infection, traumatic brain injury, corneal epithelial wound and inflammatory bowel disease .

HY-P2221B

Glepaglutide acetate 1 Publications Verification ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-13545

ABT-510 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545B

ABT-510 acetate 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-17584A

Linaclotide acetate 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide acetate is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P3282

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

HY-P11296A

LLVK TFA	IKK NF-κB	Inflammation/Immunology
LLVK TFA is a selective IκB phosphorylation inhibitor. LLVK TFA reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK TFA is promising for research of inflammatory bowel disease and rheumatoid arthritis .

HY-P11296

LLVK	IKK NF-κB	Inflammation/Immunology
LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis .

HY-P10839

NBD peptide	NF-κB	Inflammation/Immunology
NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT .

HY-P10935A

Amilo-5MER TFA 5-MP TFA	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-P1714A

Apraglutide TFA FE 203799 TFA	GLP Receptor	Metabolic Disease
Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-P10966A

Tat-IKIP (46-60) TFA	IKK NF-κB	Inflammation/Immunology
Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60) (HY-P10966). Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis .

HY-P11038

IL-23 cyclic peptide inhibitor 105	Interleukin Related	Inflammation/Immunology
IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .

HY-P11039

IL-23 cyclic peptide inhibitor 281	Interleukin Related	Inflammation/Immunology
IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .

HY-P10587A

Icotrokinra acetate JNJ-77242113 acetate; JNJ-2113 acetate; PN-235 acetate	Interleukin Related STAT IFNAR	Inflammation/Immunology
Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-P11214

Hydrostatin-TL1 H-TL1	TNF Receptor Integrin NF-κB ERK p38 MAPK JNK Interleukin Related	Inflammation/Immunology
Hydrostatin-TL1 (H-TL1), a nine-amino-acid peptide, is a TNF-α antagonist. Hydrostatin-TL1 can be isolated from the venom gland of sea snake Hydrophis cyanocinctus. H-TL1 competitively inhibits the interaction between TNF-α/TNFR1 and attenuates the cytotoxicity and inflammation of TNF-α. Hydrostatin-TL1 can be used for TNF-α-associated inflammatory diseases, such as rheumatoid arthritis, osteoporosis and inflammatory bowel disease (IBD) research .

HY-17584R

Linaclotide (Standard)	Reference Standards Guanylate Cyclase	Cancer
Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P10935

Amilo-5MER 5-MP	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

HY-P1142

GLP-2(rat)	Apoptosis	Others
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P1142A

GLP-2(rat) TFA	Apoptosis	Others
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA	Isotope-Labeled Compounds Apoptosis	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P10842

d-GLP-2 E33A	GLP Receptor Akt	Metabolic Disease Inflammation/Immunology
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC₅₀ of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .

HY-P10081

CTP-NBD	NF-κB	Inflammation/Immunology
CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study

HY-P10966

Tat-IKIP (46-60)	IKK NF-κB	Inflammation/Immunology
Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis .

HY-P11642

Sialorphin	ERK Androgen Receptor Opioid Receptor Enteropeptidase mTOR Aminopeptidase	Neurological Disease Inflammation/Immunology Cancer
Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990876

Afimkibart PF-06480605; RVT-3101	TNF Receptor NF-κB IFNAR	Inflammation/Immunology
Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-P990735

Donzakimig	Interleukin Related	Inflammation/Immunology
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G₄S)₂ linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .

HY-P991440

AMG-966	TNF Receptor	Inflammation/Immunology
AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind FcγRIa and FcγRIIa, leading to the formation of anti-drug antibodies (ADA). AMG 966 can be used in research on Crohn's disease and ulcerative colitis. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990297

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) 1 Publications Verification	CCR HIV	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P991138

Firsekibart Genakumab; GenSci048; Kinnazumab	Interleukin Related	Inflammation/Immunology
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .

HY-P991552

AFM15	CD3	Metabolic Disease Inflammation/Immunology
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .

HY-P3389

Vurolenatide	GLP Receptor	Metabolic Disease
Vurolenatide is a long-lasting GLP-1 analogue. Vurolenatide can be studied in research on short bowel syndrome .

HY-P991593

ABT-147	Interleukin Related	Inflammation/Immunology
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113402

Gamma-glutamylcysteine 4 Publications Verification γ-Glu-Cys	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-N0110

Palmatine chloride Maximum Cited Publications 9 Publications Verification	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Cancer	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N2549

(±)-Abscisic acid (±)-ABA	Natural Products other families Classification of Application Fields Metabolic Disease Abscisic acid Plants Phytohormone Disease Research Fields Source Classification Agricultural Research	Calcium Channel
(±)-Abscisic acid is an orally active plant hormone that is present also in animals. (±)-Abscisic acid (ABA) contributes to the regulation of glycemia in mammals .

HY-N0010

Geniposidic acid 5+ Cited Publications	Structural Classification other families Iridoids Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FXR Sirtuin TNF Receptor Interleukin Related
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-113402A

Gamma-glutamylcysteine TFA 4 Publications Verification γ-Glu-Cys TFA	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-111095B

D-(-)-Lactic acid sodium (R)-2-Hydroxypropionic acid sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Isomer
D-(-)-Lactic acid ((R)-2-Hydroxypropionic acid) sodium is an orally active, toxic optical isomer of Lactic acid (HY-B2227), mainly derived from overproduction by intestinal bacteria or exogenous intake. D-(-)-Lactic acid sodium can induce intoxication, characterized by severe metabolic acidosis accompanied by neurological symptoms .

HY-N0340

Scopolamine butylbromide 1 Publications Verification Hyoscine butylbromide; (-)-Scopolamine butylbromide; Butylscopolamine bromide	Alkaloids Structural Classification Other Alkaloids Datura metel L. Solanaceae Plants Source Classification	mAChR
Scopolamine butylbromide (Hyoscine butylbromide) is an orally active anticholinergic agent and spasmolytic. Scopolamine butylbromide binds with high affinity to rat cardiac M2 (K_i 83 nmol/L), hM2 (K_i 233 nmol/L), rat intestinal M3 (K_i 290 nmol/L) and hM3 (K_i 643 nmol/L) muscarinic receptors. Scopolamine butylbromide exerts a dose-dependent antagonistic effect on Carbachol-induced gastrointestinal smooth muscle spasm. Scopolamine butylbromide can be used for the research of abdominal colic and pain associated with gastrointestinal spasm, functional abdominal pain, chronic gastropathy and gastric ulcer .

HY-N0671

Rhapontin 2 Publications Verification Rhaponiticin	Stilbenes Classification of Application Fields Polygonaceae Rheum officinale Baill. Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Apoptosis
Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-N7114A

Chloramphenicol succinate sodium 3 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Metabolic Disease Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate
Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-N0110A

Palmatine	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-125740

Malvidin-3-glucoside chloride Malvidin-3-O-glucoside chloride; Oenin chloride	Classification of Application Fields Vitis vinifera cv. Zalema Plants Vitaceae Anthocyans Flavonoids Sunscreen Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Source Classification	NF-κB TNF Receptor NO Synthase Interleukin Related
Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .

HY-N5027

Oxyberberine 2 Publications Verification Oxyberberin; Berlambine; 8-Oxoberberine	Infection Structural Classification Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Others
Oxyberberine (Oxyberberin; Berlambine) is an orally effective heme oxygenase HO-1 agonist that can activate antioxidant mechanisms by regulating the PI3K/Akt/AMPK signaling pathway. Oxyberberine induces HO-1 expression, increases SOD and GSH-Px activity, inhibits NF-κB-mediated inflammatory responses, and improves insulin sensitivity and glucose metabolism. Oxyberberine has anti-diabetic, neuroprotective, anti-inflammatory and antioxidant effects, and can be used to study type 2 diabetes, traumatic brain injury (TBI) and inflammatory bowel disease .

HY-B2134

Casanthranol	Natural Products other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	Others
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.). Casanthranol can be used as a laxative in constipation and various medical conditions, stimulant laxative. Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions. Casanthranol is protective in a PFF-induced toxicity model (EC₅₀ = 34.2 μM) of N2a cells .

HY-N0110B

Palmatine hydroxide Maximum Cited Publications 9 Publications Verification	Alkaloids Phellodendron amurense Rupr. Other Alkaloids Rutaceae Plants Source Classification	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0671R

Rhapontin (Standard) 2 Publications Verification Rhaponiticin (Standard)	Stilbenes Classification of Application Fields Polygonaceae Rheum officinale Baill. Phenols Plants Disease Research Fields Source Classification Cancer	Reference Standards Apoptosis
Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-N9454

Garcinoic acid	Structural Classification Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Phenols Plants Disease Research Fields Source Classification Cancer	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-113402R

Gamma-glutamylcysteine (Standard) γ-Glu-Cys (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-W740611

Trihydroxycoprostane	Structural Classification Endogenous metabolite Steroids Source Classification	Drug Intermediate
Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders .

HY-125740R

Malvidin-3-glucoside chloride (Standard) Malvidin-3-O-glucoside chloride (Standard); Oenin chloride (Standard)	Structural Classification Anthocyans Flavonoids Vitis vinifera cv. Zalema Phenols Polyphenols Plants Vitaceae Source Classification	Reference Standards Interleukin Related NO Synthase NF-κB TNF Receptor
Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride (Standard) is the analytical standard of Malvidin-3-glucoside chloride (HY-125740). This product is intended for research and analytical applications. Malvidin-3-glucoside chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .

HY-N7114

Chloramphenicol succinate	Structural Classification Microorganisms Antibiotics Disease Research Other Antibiotics Source Classification	Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase
Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N0110R

Palmatine chloride (Standard)	Structural Classification Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Source Classification Cancer	Apoptosis Virus Protease Indoleamine 2,3-Dioxygenase (IDO) Parasite Bacterial Aurora Kinase mAChR Reference Standards
Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-113402AR

Gamma-glutamylcysteine TFA (Standard) γ-Glu-Cys TFA (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite Reference Standards AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-N7114AR

Chloramphenicol succinate sodium (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase
Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-N16477

Ciceritol	Structural Classification Leguminosae Cicer arietinum L. Plants Saccharides Monosaccharides Source Classification	Drug Metabolite
Ciceritol is a dietary fiber component/prebiotic targeting α-galactosidic linkage oligosaccharides. Ciceritol selectively promotes proliferation of beneficial bacteria like Bifidobacteria. Ciceritol is promising for research of gut microbiota-related diseases (e.g., irritable bowel syndrome, metabolic syndrome) .

HY-N17727

Divaricatol	Structural Classification Monophenols Xeranthemum annuum L. Phenols Umbelliferae Plants Source Classification	Interleukin Related TNF Receptor
Divaricatol is an orally ative chromone natural product and an active component in Saposhnikovia divaricata. Divaricatol reduces the release of pro-inflammatory cytokines and restores immune homeostasis by stably binding to 5KIR (a target of the TNF/IL-17 pathway). Divaricatol exerts analgesic effects in mouse models. Divaricatol can be used in the research of pain, diarrhea-predominant irritable bowel syndrome (IBS-D) and qi deficiency syndrome .

HY-N18720

Boswellia carterii extract	Structural Classification Boswellia sacra Flück. Extract Plants Burseraceae Source Classification	Others
Boswellia carterii, ext. is a resinous byproduct unveiling a potent anti-inflammatory prowess, aiding in studying afflictions like arthritis is asthma and inflammatory bowel diseases.

HY-N16435

Plumericin	Apocynaceae Structural Classification Natural Products Plumeria rubra L. Plants Source Classification	Bacterial Apoptosis Keap1-Nrf2 NF-κB Aryl Hydrocarbon Receptor STAT
Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis .

HY-N17131

24-O-Acetyllycoclavanol	Lycopodiaceae Triterpenes Structural Classification Ketones, Aldehydes, Acids Terpenoids Plants Source Classification	NF-κB ERK
24-O-Acetyllycoclavanol (compound 1) is a triterpenoid anti-inflammatory agent that selectively targets the NF-κB and ERK1/2 signaling pathways. It exerts its anti-inflammatory activity by inhibiting lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) and COX-2 expression, reducing the production of inflammatory mediators such as nitric oxide (NO), IL-1β, and IL-8. 24-O-Acetyllycoclavanol can be used in research related to inflammatory bowel disease (IBD). 24-O-Acetyllycoclavanol can be biologically isolated from the ethyl acetate extract of Lycopodium clavatum .

HY-N18367

Lemairamin Wgx-50	Zanthoxylum bungeanum Maxim. Structural Classification Simple Phenylpropanols Rutaceae Phenylpropanoids Plants Source Classification	nAChR Interleukin Related Akt
Lemairamin (Wgx-50) is a hydroxylamine compound. Lemairamin can be isolated from the pericarps of the Zanthoxylum plants. Lemairamin activates α7nAChR, stimulates the expression of IL-10 and POMC. Lemairamin shows a decrease in Akt. Lemairamin attenuates DSS-induced intestinal inflammation. Lemairamin alleviates pain hypersensitivity .

Cat. No.	Product Name	Chemical Structure

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-100573S

Necrosulfonamide-d4

Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-175310S

Voderdeucitinib
Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-111613S

Pinaverium bromide-d4
Pinaverium bromide-d₄ is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .

HY-178762S

RIPK1-IN-35

RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .

HY-B0380S1

Trimebutine-d5 fumarate

Trimebutine-d₅ fumarate is deuterium labeled Trimebutine fumarate. Trimebutine fumarate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine fumarate inhibits L-type Ca ²⁺ channels and large-conductance calcium-activated potassium channels (BK_Ca channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine fumarate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine fumarate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine fumarate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-14153S

Tegaserod-d11

Tegaserod-d₁₁ is deuterated labeled Tegaserod (HY-14153). Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT₄R) agonist and a 5-HT_2B receptor antagonist. Tegaserod has pK_is of 7.5, 8.4 and 7.0 for human recombinant 5-HT_2A, 5-HT_2B and 5-HT_2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research .

HY-W766920

Olsalazine Disodium-13C12
Olsalazine disodium- ¹³C₁₂ is the ¹³C-labeled Olsalazine disodium (HY-B0174). Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.

HY-19436S

Solabegron-d8
Solabegron-d₈ (GW 427353-d₈) is deuterium labeled Solabegron. Solabegron (GW 427353) is a selective β₃-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β₃-AR, with an EC₅₀ value of 22 nM . Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome .

HY-B0174AS

Olsalazine-13C6

Olsalazine- ¹³C₆ is the ¹³C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0174AS2

Olsalazine-d3,15N

Olsalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .

HY-B0380S2

Trimebutine-d3 hydrochloride

Trimebutine-d₃ hydrochloride is deuterium labeled Trimebutine hydrochloride. Trimebutine hydrochloride is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine hydrochloride inhibits L-type Ca ²⁺ channels and large-conductance calcium-activated potassium channels (BK_Ca channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine hydrochloride also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine hydrochloride also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine hydrochloride also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .

HY-I0447S

4-Aminosalicylic acid-d6
4-Aminosalicylic acid-d₆ is the deuterium labeled 4-Aminosalicylic acid (HY-I0447). 4-Aminosalicylic acid is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid is orally active .

HY-B0174AS3

Olsalazine-d6

Olsalazine-d₆ is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.

Cat. No.	Product Name		Classification

HY-108749

Olive oil Maximum Cited Publications 6 Publications Verification Cropure OL		Solvents
Olive oil (Cropure OL) is an oleaginous compound found in the fruit of the Olea europaea tree . Olive oil contains many phenolic components and exerts antioxidant activity. Olive oil exhibits hydroxyl radical scavenging, platelet aggregation inhibition and xanthine oxidase inhibitory activity. Olive oil can promote wound healing and relieve inflammation. Olive oil can be used for the research of inflammation, cancer, metabolic and cardiovascular disease, such as diabetic foot ulcers and inflammatory bowel disease .

HY-108610A

Edelfosine 1 Publications Verification ET-18-OCH3		Phospholipids
Edelfosine (ET-18-OCH3) is an orally active lipid raft modulator and apoptosis inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes. Edelfosine recruits death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form death-inducing signaling complexes, thereby initiating mitochondria-dependent apoptosis and inducing cytochrome c release. Edelfosine also exerts anti-inflammatory effects, promotes L-Selectin shedding, and causes no gastrointestinal or organ toxicity. In addition, Edelfosine inhibits nucleic acid and protein synthesis in Leishmania donovani and exhibits antiproliferative activity. Edelfosine can be used in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease), and visceral leishmaniasis .

HY-N5139

Lecithins, egg 1 Publications Verification Lecithins, egg yolk; Belovo PL 85		Emulsifiers Liposomal Film-forming Agents Solubilizing Agents
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks . Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes .

HY-145728

Alicaforsen ISIS-2302		Antisense Oligonucleotides
Alicaforsen is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease .

HY-145728A

Alicaforsen sodium ISIS-2302 sodium		Antisense Oligonucleotides
Alicaforsen (ISIS-2302) sodium is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen sodium hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen sodium is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

bowel

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products